DDInter1696 DDInter1544
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Solifenacin {u} (Compound) resembles {v} (Compound) Mequitazine
Solifenacin {u} (Compound) resembles {v} (Compound) Benazepril
Solifenacin {u} (Compound) binds {v} (Gene) CHRM4
Solifenacin {u} (Compound) palliates {v} (Disease) multiple sclerosis
Solifenacin {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Muscarinic Antagonists
Solifenacin {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Solifenacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Solifenacin {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Solifenacin (Compound) resembles Mequitazine (Compound)
Solifenacin (Compound) resembles Benazepril (Compound)
Solifenacin (Compound) binds CHRM4 (Gene)
Solifenacin (Compound) palliates multiple sclerosis (Disease)
Solifenacin (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class)
Solifenacin (Compound) causes Atrial fibrillation (Side Effect)
Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Solifenacin may lead to a major life threatening interaction when taken with Potassium chloride